Evidence map›Paper›PMID 24041438›Full record

ArticleEuropean journal of radiology2013

Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Lutz Achtnichts, Oded Gonen, Daniel J Rigotti, James S Babb, Yvonne Naegelin, Iris-Katharina Penner, Kerstin Bendfeldt, Jochen Hirsch, Michael Amann, Ludwig Kappos and 1 more

Abstract readComparative Study
In one paragraph

Article in European journal of radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lutz AchtnichtsDepartments of Neurology and Neuroradiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Oded Gonen
Daniel J Rigotti
James S Babb
Yvonne Naegelin
Iris-Katharina Penner
Kerstin Bendfeldt
Jochen Hirsch
Michael Amann
Ludwig Kappos
Achim Gass

Funding

HIGHER SPEED, FIELD &SPATIAL RESOLUTION BRAIN 3D 1H MRSR01EB001015 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2002 to 2011
$5.8M
Serial Brain 3D 1H MR Spectroscopy in Multiple SclerosisR01NS050520 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2005 to 2009
$2.9M
Serial Brain 3D 1H MR Spectroscopy in Multiple Sclerosis.R56NS050520 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GONEN, ODED · 2011 to 2011
$586k
NIBIB NIH HHS EB01015NIBIB NIH HHS R01 EB001015NINDS NIH HHS NS005052NINDS NIH HHS R01 NS050520NINDS NIH HHS R56 NS050520
6 · The paper itself

Abstract

BACKGROUND AND

objectiveTo examine whether clinically benign multiple sclerosis patients (BMS) show similar losses of their global N-acetylaspartate (NAA) neuronal marker relative to more clinically disabled patients of similar disease duration.

methodsThe whole-brain NAA concentration (WBNAA) was acquired with whole-head non-localizing proton MR spectroscopy. Fractional brain parenchymal volume (fBPV), T2 and T1 lesion loads, were obtained from the MRI in: (i) 24 BMS patients: 23.1 ± 7.2 years disease duration, median Expanded Disability Status Scale (EDSS) score of 2.0 (range: 0-3); (ii) 26 non-benign MS patients (non-BMS), 24.5 ± 7.4 years disease duration, median EDSS of 4.0 (range: 3.5-6.5); (iii) 15 healthy controls.

resultsControls' 12.4 ± 2.3mM WBNAA was significantly higher than the BMS's and non-BMS's 10.5 ± 2.4 and 9.9 ± 2.1mM (both p<0.02), but the difference between the patients' groups was not (p>0.4). Likewise, the controls' 81.2 ± 4.5% fBPV exceeded the BMS and non-BMS's 77.0 ± 5.8% and 76.3 ± 8.6% (p<0.03), which were also not different from one another (p>0.7). BMS patients' T1-hypointense lesion load, 2.1 ± 2.2 cm(3), was not significantly different than the non-BMS's 4.1 ± 5.4 cm(3) (p>0.08) and T2-hyperintense loads: 6.0 ± 5.7 cm(3) and 8.7 ± 7.8 cm(3), were also not different (p>0.1).

conclusionsWBNAA differentiates normal controls from MS patients but does not distinguish BMS from more disabled MS patients of similar disease duration. Nevertheless, all MS patients who remain RR for 15+ years suffered WBNAA loss similar to the average RR MS population at fourfold shorter disease duration suggesting relative global neuronal sparing or leveling-off of the neurodegeneration rate.

Indexed as

Brain ChemistryAdultAspartic AcidBiomarkersDiagnosis, DifferentialFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMultiple Sclerosis, Chronic ProgressiveProtonsReproducibility of ResultsSensitivity and SpecificitySeverity of Illness IndexAspartic AcidBiomarkersN-acetylaspartateProtonsBenignMR spectroscopyMultiple sclerosisWBNAA

Identifiers

PMID24041438
PMCPMC3825814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.